Phenotypic Screening to Identify & Optimize Protein Degraders for CNS Disorders Acting Through the Autophagy-Lysosome Pathway

• Keys to designing fruitful phenotypic screens for protein degraders
• Rapid hit prioritization to lead and lead optimization
• Insights into PK/PD for protein degraders

Speakers:

Beth Hoffman

Founder, President & Chief Executive Officer

Origami Therapeutics, Inc.